| Filed On | Filing |
|---|---|
| 20 Oct 2026 | 424B3 |
| 20 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – |
| 23 Sep 2026 | S-8 |
| 04 Sep 2026 |
Form 4: Elliott Aaron Matthew, Director
Gave up 71,920 shares to cover exercise price or tax ($1.1M) |
| 01 Sep 2026 | SCHEDULE 13G |
| 27 Aug 2026 | EFFECT |
| 27 Aug 2026 | 424B3 |
| 18 Aug 2026 | S-1 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 |
8-K/A: Completion of Acquisition or Disposition of Assets
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | SCHEDULE 13G/A |
| 29 Jul 2026 | EFFECT |
| 29 Jul 2026 |
Form 4: Waksal Harlan, Former Director
Received 30,000 shares by conversion |
| 28 Jul 2026 | POS AM |
| 27 Jul 2026 |
Form 3: Nuechterlein Carole, Director
No securities owned |
| 27 Jul 2026 |
Form 3: Costello Ann Catherine, Director
No securities owned |
| 27 Jul 2026 |
Form 3: Van Oort Douglas M, Director
Holds 20,867 shares of Common Stock |
Loading...
